Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Half of those surveyed plan to raise deductibles and maximum out-of-pocket costs for workers. Read more at straitstimes.com. Read more at straitstimes.com.

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

The Cigna Group's fundamentals are solid, but the stock is fairly valued versus peers, not a bargain. Click here to find out ...

Cigna trades at a significant discount to the S&P 500, offering a higher yield and faster dividend growth, making it ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...